论文部分内容阅读
Leukemia stem cells(LSCs)insensitive to imatinib are believed to be responsible for resistance to BCR-ABL tyrosine kinase inhibitors and relapse of chronic myelogenous leukemia(CML).Identifying therapeutic targets to eradicate CML LSCs may be a strategy to cure CML.In the present study,we discovered a positive feedback loop between protein arginine methyltransferase 5(PRMT5)and BCR-ABL in CML cells.Further,PRMT5 overexpression was observed in human CML LSCs.